AGM
EVLO

Alpine Global Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Alpine Global Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-710
Closed -$86K – 800
2021
Q4 		$86K Buy
+710
New +$120K 0.01% 692

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alpine Global Management's EVLO Position: Q1 2022 in Review

Alpine Global Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2022, closing a stake of 710 shares — an estimated $86K sold.

Alpine Global Management first reported a position in EVLO in Q4 2021 and held it in 1 quarter. The position peaked at $86K in Q4 2021. 68 funds tracked by Wall St. Rank hold EVLO as of Q1 2022.

  • Alpine Global Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 710 Evelo Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $86K.
  • Alpine Global Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Alpine Global Management's Evelo Biosciences, Inc. Common Stock position peaked at $86K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.